Страна: Ирландия
Език: английски
Източник: HPRA (Health Products Regulatory Authority)
Ammi visnagai d1 dilution; Aralia racemose d2 trituration; Cardiospermum halicacabum d2 trituration; Thryallis glauca d3 trituration; Larrea mexicana d2 trituration; Luffa operculata d6 trituration; Okoubaka aubrevillei d2 trituration
A.Vogel Ireland Limited
Ammi visnagai d1 dilution; Aralia racemose d2 trituration; Cardiospermum halicacabum d2 trituration; Thryallis glauca d3 trituration; Larrea mexicana d2 trituration; Luffa operculata d6 trituration; Okoubaka aubrevillei d2 trituration
milligram(s)
Tablet
Marketed
2019-05-31
A.Vogel Ireland Pollinosan tablets IE - Dublin CTD Module 1 July 2022 ___________________________________________________________________________________ PACKAGE LEAFLET PIL2580.e04 Page 1 of 5 Pollinosan (2) HK Tabl Art. no. 01314900 PACKAGE LEAFLET: INFORMATION FOR THE USER POLLINOSAN HAYFEVER TABLETS READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS PRODUCT BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always use this product exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. • Keep this leaflet. You may need to read it again. • Ask your pharmacist if you need more information or advice. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • You must talk to a doctor if you do not feel better or if you feel worse after 7 days, WHAT IS IN THIS LEAFLET 1. What Pollinosan is and what it is used for 2. What you need to know before you take Pollinosan 3. How to take Pollinosan 4. Possible side effects 5. How to store Pollinosan 6. Contents of the pack and other information 1. WHAT POLLINOSAN IS AND WHAT IT IS USED FOR Pollinosan is a homeopathic medicinal product containing the extracts of _Ammi visnaga_, _Aralia racemosa_, _Cardiospermum halicacabum_, _Galphimia _ _glauca_, _Larrea mexicana_, _Luffa operculata_ and _Okoubaka aubrevillei_. It is used within the homeopathic tradition to relieve the symptoms of: • Hayfever • Other forms of allergic rhinitis Pollinosan is for use in adults and adolescents over 12 years. Hayfever and allergic rhinitis are conditions where the body’s immune system reacts abnormally to external irritants (allergens) such as pollen, animal dander (material shed from the body of animals) and dust. Symptoms can include sneezing, blocked nose, runny and itchy nose, itchy eyes and throat. A.Vogel Ireland Pollinosan tablets IE - Dublin CTD Module 1 July 2022 _________________________________________________________________ Прочетете целия документ
Health Products Regulatory Authority 21 September 2023 CRN00DV3M Page 1 of 3 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pollinosan Hayfever tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet (250 mg) contains: _Ammi visnaga _1x _Aralia racemosa _2x _Cardiospermum halicacabum _2x _Galphimia glauca _3x _Larrea mexicana _2x _Luffa operculata _6x _Okoubaka aubrevillei _2x Excipients with known effect: Contains lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet Slightly yellowish, biconvex tablet with a triangular stamp. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS A homoeopathic medicinal product used within the homeopathic tradition to relieve the symptoms of hayfever and other forms of allergic rhinitis. This product is indicated for use in adults and adolescents over 12 years. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Adults, older people and adolescents over 12 years: Take 2 tablets 3 times daily before meals. Maximum recommended daily dose is 6 tablets. This product should not be used in children under 12 years. METHOD OF ADMINISTRATION For oral use only. 4.3 CONTRAINDICATIONS Hypersensitivity to any of the active substances or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Do not exceed the stated dose. If the condition worsens or if symptoms persist for more than 7 days, a qualified healthcare professional e.g. a doctor or pharmacist should be consulted. This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine. This product is not recommended for use in children under 12 years of age due to a lack of data on safety. Health Products Regulatory Authority 21 September 2023 CRN00DV3M Page 2 of 3 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION No interaction studies have been performed. 4.6 FERTILITY, PREGNANCY AND Прочетете целия документ